ArticlePloS one2025
Mediators of the stimulatory effect of S1P on colonic Na+/K+ ATPase.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Na ⁺ /K ⁺ ATPase, commonly known as the Na ⁺ /K⁺ pump, plays a crucial role in colonic sodium and water transport, inducing diarrhea or constipation. Inflammatory bowel disease is often associated with diarrhea and elevated levels of sphingosine-1-phosphate (S1P), suggesting a potential relationship between the pump and S1P. This study investigated the effects of S1P on colonic Na ⁺ /K ⁺ ATPase using Caco-2 cells as a model and the S1P analogue used in the treatment of multiple sclerosis, FTY720P. The pump activity was assessed by measuring the amount of inorganic phosphate released in the presence and absence of ouabain, an ATPase inhibitor. FTY720P induced an inhibition of Na ⁺ /K ⁺ ATPase at 15 minutes that was studied in a previous work. This inhibition shifted however, to stimulation at 2 hours, an effect that was abolished in the presence of JTE-013, an S1PR2 antagonist, and was replicated by CYM5520, an S1PR2 agonist. Further mechanistic exploration revealed that when PKC, NF-κB, COX, PKA, and PI3K enzymes were inhibited, FTY720P no longer influenced Na ⁺ /K ⁺ ATPase activity, indicating their involvement in the signaling cascade. Additional evidence supporting this pathway came from activators of these kinases and exogenous PGE₂, both of which stimulated the pump. The results indicate that FTY720P stimulates Na ⁺ /K ⁺ ATPase at 2 hours by binding to S1PR2, leading to PKC activation, followed by NF-κB-mediated induction of PGE₂ synthesis. PGE₂ then binds to its EP4 receptors, activating PKA and PI3K, ultimately resulting in an increase in the pump's activity. These findings will open the door to targeted regulation of these intermediate molecules which could potentially alleviate certain undesirable effects of the drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.